EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma

Jianhua Zhang, Jin Du, Zhihai Jin, Jiang Qian, Jinfa Xu

PeerJ · 2023

DOI: 10.7717/peerj.15615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Jianhua Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, People's Hospital of Chizhou, Chizhou, China. Hauptthemen laut MEDLINE: Immunogenic Cell Death, Glioma. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioma is a primary cranial malignancy with high recurrence rate, poor prognosis and high mortality. However, the roles of immunogenic cell death (ICD) in glioma remain unclear. Twenty ICD genes were analyzed to be differentially expressed between glioma tissues and non-tumor tissues in 371 glioma patients from The Cancer Genome Atlas (TCGA). Patients were classified into three subgroups via unsupervised clustering. Interestingly, the features of cell-infiltrating from three clusters were matched with three immune phenotypes. An applied scoring system was built depending on the expression of hub ICD-related genes. Notably, the ICD-related score was linked with immune checkpoints and the prognosis of glioma patients. In addition, the applied risk model could be used for the prediction of the effect of chemotherapy and immunotherapy for glioma patients. Furthermore, MYD88 was identified to play key roles in the risk model for glioma patients. MYD88 was specifically expressed in malignant cells and validated to correlate with cell proliferation and invasion. Ligand–receptor pairs are determined as novel communications indicating between immunocytes and malignant cells. Therefore, our research established an ICD-related score to investigate the potential effect to chemotherapy and immunotherapy for glioma patients and indicated that MYD88 was a key role in this risk model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunogenic Cell DeathGliomaHumansMyeloid Differentiation Factor 88PrognosisImmunotherapyAdaptor Proteins, Signal Transducing

Stichwörter der Autor:innen

ChemotherapyGliomaImmunogenic cell deathImmunotherapyPredictionPrognosis

Substanzen

Myeloid Differentiation Factor 88Adaptor Proteins, Signal Transducing

Autor:innen und Institutionen

  • Department of Oncology, People's Hospital of Chizhou, Chizhou, China.
  • Department of Neurosurgery, People's Hospital of Chizhou, Chizhou, China.
  • Department of Orthopedics, Handan First Hospital, Handan, China.

Zitieren

APA

Zhang, J., Du, J., Jin, Z., Qian, J., & Xu, J. (2023). A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma. PeerJ. https://doi.org/10.7717/peerj.15615

Vancouver

Zhang J, Du J, Jin Z, Qian J, Xu J. A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma. PeerJ. 2023. doi:10.7717/peerj.15615

BibTeX
@article{Zhang2023,
  author = {Zhang, Jianhua and Du, Jin and Jin, Zhihai and Qian, Jiang and Xu, Jinfa},
  title = {A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.15615}
}
Kostenlos starten →